GlassScriptPhysician profile
Todd A Kovach
NPI 1376505362
$4,026.79
in general payments reported to CMS, 2019-2025
32 companies · $1,087 in 2025
The $1,087 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $196 · 2021: $66.58 · 2022: $255 · 2023: $368 · 2024: $828 · 2025: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,281 · Education: $3.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,280.70 |
| Education | $3.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $622.20 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $456.04 | 2019-2024 | Xarelto |
| Pfizer INC. | $362.35 | 2022-2025 | |
| Amgen INC. | $283.84 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.19 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $219.89 | 2019-2025 | Farxiga |
| Medtronic Vascular, INC. | $191.80 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $165.25 | 2019-2025 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $159.28 | 2024 | Optimizer |
| Sanofi-Aventis U.S. LLC | $136.41 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $125.40 | 2024-2025 | Onpattro |
| Astellas Pharma US INC | $123.23 | 2019 | |
| Novo Nordisk INC | $108.07 | 2024-2025 | Wegovy, Ozempic |
| Scpharmaceuticals INC. | $91.04 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $89.51 | 2023-2024 | Inpefa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.47 | 2019-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $63.30 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $59.03 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $57.03 | 2019-2023 | Opsumit, Uptravi |
| Lundbeck LLC | $54.71 | 2019-2020 | |
| Amarin Pharma, INC. | $48.74 | 2019-2021 | |
| Nuwellis, INC. | $47.83 | 2019-2020 | |
| Boston Scientific Corporation | $30.74 | 2019 | |
| Kestra Medical Technology Services, INC. | $29.47 | 2023 | Assure Wcd |
| Merck Sharp & Dohme LLC | $25.10 | 2023 | Verquvo |
| Vital Connect, INC | $22.48 | 2025 | Vitalpatch Rtm |
| Kiniksa Pharmaceuticals, LTD. | $20.67 | 2023 | Arcalyst |
| Aegerion Pharmaceuticals, INC. | $20.53 | 2019 | |
| Cleerly, INC. | $20.48 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Portola Pharmaceuticals, LLC | $20.43 | 2019 | |
| Abbott Laboratories | $16.33 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Kovach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.